Persisting high rates of mental health disorders in patients in opioid agonist treatment-Results from a 6-year longitudinal study.

IF 1.9 4区医学 Q2 SUBSTANCE ABUSE

American Journal on Addictions Pub Date : 2025-09-14 DOI:10.1111/ajad.70085

Michael Soyka, Gabi Koller, Wittchen Hans-Ulrich, Gerhard Bühringer

{"title":"Persisting high rates of mental health disorders in patients in opioid agonist treatment-Results from a 6-year longitudinal study.","authors":"Michael Soyka, Gabi Koller, Wittchen Hans-Ulrich, Gerhard Bühringer","doi":"10.1111/ajad.70085","DOIUrl":null,"url":null,"abstract":"Background and objectives: There are hardly any data from longitudinal studies on the prevalence of mental health disorders in patients in opioid agonist therapy (OAT).Methods: Here we report prevalence rates of mental health disorders in a 6-year naturalistic noninterventional follow-up study of patients in OAT (N = 2694 at baseline).Results: The number of participants without any psychiatric diagnosis only modestly increased from 36.7% to 42.2% (males 42.6%, females 47.6%) over a 6-year period. Depression (42%), anxiety disorders (19.3%), sleep disorders (21.3%), and posttraumatic stress disorder (13%) were most frequent. The rates for patients in psychiatric or psychological/psychotherapeutic treatment at baseline were rather low (8% resp. 8-12%) and declined over time (3.6% resp. 5.4%-6.8% after 6 years).Conclusions and scientific significance: Data from this long-term study indicate an overall high persisting prevalence of mental health disorders in patients in OAT and a rather low number of patients in psychiatric/psychological treatment. Hence, this study indicates a substantial need for specific psychosocial and psychopharmacological interventions in patients in opioid agonist therapy.","PeriodicalId":7762,"journal":{"name":"American Journal on Addictions","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal on Addictions","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajad.70085","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objectives: There are hardly any data from longitudinal studies on the prevalence of mental health disorders in patients in opioid agonist therapy (OAT).

Methods: Here we report prevalence rates of mental health disorders in a 6-year naturalistic noninterventional follow-up study of patients in OAT (N = 2694 at baseline).

Results: The number of participants without any psychiatric diagnosis only modestly increased from 36.7% to 42.2% (males 42.6%, females 47.6%) over a 6-year period. Depression (42%), anxiety disorders (19.3%), sleep disorders (21.3%), and posttraumatic stress disorder (13%) were most frequent. The rates for patients in psychiatric or psychological/psychotherapeutic treatment at baseline were rather low (8% resp. 8-12%) and declined over time (3.6% resp. 5.4%-6.8% after 6 years).

Conclusions and scientific significance: Data from this long-term study indicate an overall high persisting prevalence of mental health disorders in patients in OAT and a rather low number of patients in psychiatric/psychological treatment. Hence, this study indicates a substantial need for specific psychosocial and psychopharmacological interventions in patients in opioid agonist therapy.

查看原文本刊更多论文

阿片类激动剂治疗患者持续高比例的精神健康障碍——一项为期6年的纵向研究结果

背景和目的：关于阿片类激动剂治疗（OAT）患者精神健康障碍患病率的纵向研究几乎没有任何数据。方法：在这里，我们报告了一项为期6年的自然非介入性随访研究中OAT患者的精神健康障碍患病率（基线时N = 2694）。结果：在6年的时间里，没有任何精神诊断的参与者数量仅从36.7%轻微增加到42.2%（男性42.6%，女性47.6%）。抑郁症（42%）、焦虑症（19.3%）、睡眠障碍（21.3%）和创伤后应激障碍（13%）最为常见。接受精神科或心理/心理治疗的患者在基线时的比率相当低（8%）。8-12%)，并随着时间的推移而下降（平均3.6%）。6年后5.4%-6.8%)。结论和科学意义：这项长期研究的数据表明，OAT患者中精神健康障碍的总体持续患病率较高，而接受精神/心理治疗的患者数量相当低。因此，这项研究表明，在阿片类药物激动剂治疗中，需要对患者进行特定的社会心理和精神药理学干预。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal on Addictions SUBSTANCE ABUSE-

CiteScore

5.00

自引率

0.00%

发文量

118

期刊介绍： The American Journal on Addictions is the official journal of the American Academy of Addiction Psychiatry. The Academy encourages research on the etiology, prevention, identification, and treatment of substance abuse; thus, the journal provides a forum for the dissemination of information in the extensive field of addiction. Each issue of this publication covers a wide variety of topics ranging from codependence to genetics, epidemiology to dual diagnostics, etiology to neuroscience, and much more. Features of the journal, all written by experts in the field, include special overview articles, clinical or basic research papers, clinical updates, and book reviews within the area of addictions.